Schizophrenia has been treated for more than 70 years with dopamine receptor antagonists or partial agonists, whose efficacy is thought to be related to a reduction of postsynaptic dopamine transmission. These so-called first- and second-generation ”antipsychotics” have been foundational for the management of schizophrenia and psychosis in general, but treatment gaps remain.
In this video Professor Christoph Correll discusses the challenges we have with the available schizophrenia treatments today. He also touches upon what clinicians should keep in mind when considering the emerging treatment options for their patients living with schizophrenia.
Related content
Schizophrenia is associated with interacting genetic, environmental, and neurobiological factors that affect brain development, neurotransmission, immune function, and neural circuits.
In this video, Professor Dr. Ana Catalan explores whether psychotic disorders can be prevented and reviews the latest evidence on early intervention in psychosis. She explains how personalized, evidence-based care can enhance quality of life, daily functioning, and long-term recovery for people at risk of or experiencing psychosis.
Schizophrenia is associated with substantial disability, reduced life expectancy, and increased rates of psychiatric and physical comorbidities.